key: cord-0793427-onu6k3es
authors: Linschoten, Marijke; Nab, Linda; van der Horst, Iwan C.C.; Tieleman, Robert; Asselbergs, Folkert W.
title: Response to “Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients”
date: 2020-12-09
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.12.006
sha: 17ad3194de70b6ce077833384e26bfa247c514ba
doc_id: 793427
cord_uid: onu6k3es

nan

Given the limited number of effective drugs available, these results are of utmost interest. We think additional requirements are to be met before drawing the conclusion that HCQ is beneficial.

First, the median age at ICU admission decreased during the first wave in the Netherlands, as illustrated by Dutch data from the CAPACITY registry ( Figure) , indicating changing characteristics of the ICU population. 2 All analyses were stratified by ICU restriction.

However, in the presence of ICU restriction for medical reasons or patient preference, analyses on the outcome 'transfer to ICU' are limited to patients without ICU restriction, a particularly selected group. This might impact the generalizability of the results considerably.

Second, there were strong regional differences in infection rates in the Netherlands.

Differences in the need to consider ICU restrictive policies could be found earlier in regions with high admission rates. Additionally, these regional differences led to the necessity of transferring patients to hospitals in other areas. Patients were only transferred if it was anticipated that there was a chance of recovery and thereby, transferred patients are likely to differ from non-transferred patients. It is plausible that the exclusion of transferred patients introduces selection bias. Moreover, regional differences in infection rates might by chance also coincide with local protocols on the use of HCQ, chloroquine or no treatment.

Third, it is unclear whether the exposure was defined based on centre of admission or based on received treatment. Propensity score matching was used to balance covariates across levels of exposure, but no information on propensity score distribution nor trimming was provided. Moreover, if received treatment was the exposure, immortal time bias may play a role since median time to HCQ administration was one day. Consequently, those who were treated had a median survival of at least one day, whereas those untreated were at risk of ICU transfer directly from admission. 3 Furthermore, follow-up was stopped once a patient was admitted to the ICU and ICU mortality ignored. Finally, hospital discharge should also have been treated as a competing risk for death and ICU admission. 4 Before determining whether this study can contribute to establishing whether HCQ is useful in the treatment of Covid-19, these issues need to be addressed.

Ethical Approval: Not applicable. Total number of patients with Covid-19 admitted to the ICU in the Netherlands (indicated by black dots) during the first wave between 9 March and 3 May 2020 (based on publicly available data from the NICE foundation 5 ). The median age of ICU admitted patients (indicated by blue dots, blue vertical bars interquartile ranges) declined during that period (based on data of 1182 patients from the Dutch CAPACITY registry 2 ). The blue dots indicate median age of the patients admitted to the ICU at that date and the six leading days. Prior to the COVID-19 pandemic, there were 1150 ICU beds in the Netherlands (indicated by the black line).

Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients

CAPACITY-COVID: a European Registry to determine the role of cardiovascular disease in the COVID-19 pandemic

Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes

Competing risks in epidemiology: possibilities and pitfalls

Covid-19 infecties op de IC's

The authors declare no conflicts of interest.